404 related articles for article (PubMed ID: 15800138)
21. Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report.
Na HR; Kim S; Choi SH; Yang DW; Bae HJ; Kim JE; Park MY; Shim YS; Kim BK; Kwon JC; Yoo BG; Kim BC; Lee JS
Geriatr Gerontol Int; 2011 Jan; 11(1):90-7. PubMed ID: 20825496
[TBL] [Abstract][Full Text] [Related]
22. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
[TBL] [Abstract][Full Text] [Related]
23. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
[TBL] [Abstract][Full Text] [Related]
24. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
25. Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease.
Hanyu H; Tanaka Y; Sakurai H; Takasaki M; Abe K
Neurosci Lett; 2002 Feb; 319(1):33-6. PubMed ID: 11814647
[TBL] [Abstract][Full Text] [Related]
26. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
[TBL] [Abstract][Full Text] [Related]
27. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
28. Donepezil use in Alzheimer disease.
Barner EL; Gray SL
Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825
[TBL] [Abstract][Full Text] [Related]
29. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
[TBL] [Abstract][Full Text] [Related]
30. Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
Tariot PN; Jakimovich L
J Am Med Dir Assoc; 2003; 4(4):216-9. PubMed ID: 12837144
[TBL] [Abstract][Full Text] [Related]
31. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Sugimoto H
Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
[TBL] [Abstract][Full Text] [Related]
32. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
33. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
Mizuno S; Kameda A; Inagaki T; Horiguchi J
Psychiatry Clin Neurosci; 2004 Dec; 58(6):660-5. PubMed ID: 15601392
[TBL] [Abstract][Full Text] [Related]
34. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients.
Tanaka Y; Hanyu H; Sakurai H; Takasaki M; Abe K
Dement Geriatr Cogn Disord; 2003; 16(3):119-25. PubMed ID: 12826736
[TBL] [Abstract][Full Text] [Related]
35. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
36. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
Choi SH; Kim SY; Na HR; Kim BK; Yang DW; Kwon JC; Park MY
Dement Geriatr Cogn Disord; 2008; 25(5):445-50. PubMed ID: 18401173
[TBL] [Abstract][Full Text] [Related]
37. Potential predictors of hippocampal atrophy in Alzheimer's disease.
Dhikav V; Anand K
Drugs Aging; 2011 Jan; 28(1):1-11. PubMed ID: 21174483
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
39. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
[TBL] [Abstract][Full Text] [Related]
40. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
Weiner MF; Martin-Cook K; Foster BM; Saine K; Fontaine CS; Svetlik DA
J Clin Psychiatry; 2000 Jul; 61(7):487-92. PubMed ID: 10937606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
